Quick Answer
Syndax Pharmaceuticals Inc reported Revenue (ASC 606) of $172.35 million for fiscal year 2025.
Syndax Pharmaceuticals Inc Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $172.35M | +627.8% |
| 2024 | $23.68M | — |
| 2023 | $0.00 | — |
| 2022 | $0.00 | -100.0% |
| 2021 | $139.71M | +9109.6% |
| 2020 | $1.52M | +0.0% |
| 2019 | $1.52M | +0.0% |
| 2018 | $1.52M | -28.0% |
| 2017 | $2.11M | +72.8% |
| 2016 | $1.22M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $45.87M | +267.0% | +20.8% |
| June 30, 2025 | $37.96M | +984.5% | +89.4% |
| March 31, 2025 | $20.04M | — | +60.3% |
| September 30, 2024 | $12.50M | — | +257.1% |
| June 30, 2024 | $3.50M | — | — |
| March 31, 2024 | $0.00 | — | — |
| September 30, 2023 | $0.00 | — | — |
| June 30, 2023 | $0.00 | — | -100.0% |
- Syndax Pharmaceuticals Inc showed an increase of +627.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, Syndax Pharmaceuticals Inc’s revenue (asc 606) has grown by 14027.2% (from $1.22 million to $172.35 million).
- The most recent figure is from Syndax Pharmaceuticals Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: